New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 9, 2014
08:15 EDTAMPEAmpio's Ampion shows positive results in arthritis study extension
Ampio announced results of the 20 weeks extension of the Ampion SPRING study to be presented at the Western Orthopedic Association Conference in July. This 20-week extension of a multicenter study evaluated the safety and efficacy of a single intra-articular injection of Ampion treatment of inflammation-associated pain in symptomatic OA of the knee. At 20 weeks, the percentage of patients in the moderate-to-severe subgroup who reported a reduction in pain was significantly higher for patients who received Ampion - 50% - compared to those who received vehicle control - 25% -. Similar rates and severity of adverse events were observed in the Ampion and vehicle control groups. A single injection of Ampion was associated with sustained improvements in knee pain over 20 weeks.
News For AMPE From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 25, 2015
07:17 EDTAMPEAmpio's Ampion for osteoarthritis shows positive top-line results
Ampio announced results of the double-blind, multiple injection, vehicle controlled STRUT study at 20 weeks. The forty patient randomized phase of the STRUT study was conducted to assure that multiple injections of Ampion were safe and effective. Each patient received three 4 mL intra-articular injections of Ampion or saline at baseline, 2 weeks and 4 weeks. There were no drug related serious adverse events. The primary endpoint that is required for FDA approval, WOMAC A pain score, improved by 64% from baseline to 20 weeks. Responder rate for Ampion was 79% compared to 47% of saline patients. Data for the larger, multi-site STRIDE study, a similar design to STRUT study, is expected in Q2.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use